Telomir Pharmaceuticals Files 8-K
Ticker: TELO · Form: 8-K · Filed: Sep 4, 2025 · CIK: 1971532
Sentiment: neutral
Topics: 8-k, other-events
TL;DR
Telomir Pharma filed an 8-K for an event on 8/28. Details TBD.
AI Summary
Telomir Pharmaceuticals, Inc. filed an 8-K on September 4, 2025, reporting an event on August 28, 2025. The filing is categorized under 'Other Events' and does not provide specific details about the nature of the event in the provided text.
Why It Matters
This filing indicates a material event has occurred for Telomir Pharmaceuticals, requiring disclosure to investors.
Risk Assessment
Risk Level: medium — The filing is an 8-K 'Other Event', which can range from minor administrative changes to significant business developments, making the immediate risk level uncertain without further details.
Key Players & Entities
- Telomir Pharmaceuticals, Inc. (company) — Registrant
- August 28, 2025 (date) — Date of earliest event reported
- September 4, 2025 (date) — Filing Date
- Miami, Florida (location) — Principal Executive Offices
FAQ
What specific event is being reported under 'Other Events' in this 8-K filing?
The provided text of the 8-K filing does not specify the nature of the 'Other Events' reported; it only indicates that an event occurred on August 28, 2025.
When was this Form 8-K filed with the SEC?
This Form 8-K was filed on September 4, 2025.
What is the principal business address of Telomir Pharmaceuticals, Inc.?
The principal executive offices are located at 100 SE 2nd St, Suite 2000, #1009, Miami, Florida.
What is the Commission File Number for Telomir Pharmaceuticals, Inc.?
The Commission File Number for Telomir Pharmaceuticals, Inc. is 001-41952.
What is the IRS Employer Identification Number (EIN) for Telomir Pharmaceuticals, Inc.?
The IRS Employer Identification Number for Telomir Pharmaceuticals, Inc. is 87-2606031.
Filing Stats: 440 words · 2 min read · ~1 pages · Grade level 12.3 · Accepted 2025-09-04 10:13:53
Key Financial Figures
- $1.87 — ional investors, at an average price of $1.87 per share (a premium to the prior day's
- $2.9 m — from the Offering totaled approximately $2.9 million, prior to deducting fees and expe
Filing Documents
- form8-k.htm (8-K) — 32KB
- 0001641172-25-026527.txt ( ) — 195KB
- telo-20250828.xsd (EX-101.SCH) — 3KB
- telo-20250828_lab.xml (EX-101.LAB) — 33KB
- telo-20250828_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TELOMIR PHARMACEUTICALS, INC. Dated: September 4, 2025 By: /s/ Erez Aminov Name: Erez Aminov Title: Chief Executive Officer